Selatinib

Overview

Selatinib is an orally active EGFR and HER2 tyrosine kinase inhibitor with IC 50 values of 13.0 nM and 8.5 nM, respectively. Selatinib undergoes oxidative metabolism in vivo to produce Lapatinib ( HY-50898 ). Selatinib inhibits the growth of breast, gastric and ovarian tumors. Selatinib can be used in research related to gastric cancer , breast cancer and ovarian cancer .

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Gastric Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-116437
• CAS No.: 1275595-86-2
• Molecular Formula: C29H26ClFN4O3S
• Molecular Weight: 565.06
• Purity: 98.56%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source